Patents by Inventor Pontus FORSELL

Pontus FORSELL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 4-substituted phenyl-1,3,5-triazine derivatives as modulators of TrK receptors
    Patent number: 11840524
    Abstract: There is provided a compound of formula (I), wherein R1, R2, R3, Q1, Q2, Q3, X, A and n are as defined herein, which compounds are useful in the treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: December 12, 2023
    Assignee: ALZECURE PHARMA AB
    Inventors: Gunnar Nordvall, Pontus Forsell
  • TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS
    Publication number: 20220324819
    Abstract: There is provided a compound of formula I, (I) wherein R1 and R2 are as defined herein, which compounds are useful in the treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like.
    Type: Application
    Filed: August 28, 2020
    Publication date: October 13, 2022
    Inventors: Gunnar Nordvall, Pontus Forsell
  • TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS
    Publication number: 20220306589
    Abstract: There is provided herein a compound of formula I, wherein R1, R2, n, X, Q, L, m, R3 and p are as defined herein, which compounds are useful in the treatment of treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like.
    Type: Application
    Filed: June 2, 2022
    Publication date: September 29, 2022
    Inventors: Gunnar Nordvall, Pontus Forsell
  • 4-SUBSTITUTED PHENYL-1,3,5-TRIAZINE DERIVATIVES AS MODULATORS OF TRK RECEPTORS
    Publication number: 20210371402
    Abstract: There is provided a compound of formula (I), wherein R1, R2, R3, Q1, Q2, Q3, X, A and n are as defined herein, which compounds are useful in the treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like.
    Type: Application
    Filed: June 28, 2019
    Publication date: December 2, 2021
    Inventors: Gunnar NORDVALL, Pontus FORSELL
  • 4-SUBSTITUTED PHENYL-1,3,5-TRIAZINE DERIVATIVES AS MODULATORS OF TRK RECEPTORS
    Publication number: 20210261513
    Abstract: There is provided a compound of formula I, wherein R1, R2 R3, Q1, Q2 and Q3 are as defined herein, which compounds are useful in the treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like.
    Type: Application
    Filed: June 28, 2019
    Publication date: August 26, 2021
    Inventors: Gunnar NORDVALL, Pontus FORSELL
  • TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS
    Publication number: 20200399230
    Abstract: There is provided herein a compound of formula (I) wherein R1, R2, n, X, Q, L, m, R3 and p are as defined herein, which compounds are useful in the treatment of treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like.
    Type: Application
    Filed: February 26, 2019
    Publication date: December 24, 2020
    Applicant: AlzeCure Pharma AB
    Inventors: Gunnar Nordvall, Pontus Forsell
  • TRIAZINETRIONE DERIVATIVES AND THEIR USE AS MODULATORS OF NEUROTROPHIN RECEPTOR AND RECEPTOR TYROSINE KINASES
    Publication number: 20200113910
    Abstract: The present invention relates to anew use of 4-phenoxy-phenyl-1,3,5-triazine derivatives or pharmaceutically acceptable salts thereof, according to formula I, wherein R1, R2 and U have meanings as provided in the description, as medicaments for the treatment and/or prevention of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors. In particular, the invention relates to the treatment of such diseases in patients with the Val66Met mutation in the brain-derived neurotrophic factor gene.
    Type: Application
    Filed: December 21, 2017
    Publication date: April 16, 2020
    Inventors: Gunnar NORDVALL, Pontus FORSELL, Johan SANDIN